ES2130548T3 - Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Info

Publication number
ES2130548T3
ES2130548T3 ES95400496T ES95400496T ES2130548T3 ES 2130548 T3 ES2130548 T3 ES 2130548T3 ES 95400496 T ES95400496 T ES 95400496T ES 95400496 T ES95400496 T ES 95400496T ES 2130548 T3 ES2130548 T3 ES 2130548T3
Authority
ES
Spain
Prior art keywords
alkoxy
alkyl
halogen
opt
substd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95400496T
Other languages
English (en)
Inventor
Gerald Guillaumet
Marie-Claude Viaud
Pierre Renard
Gerard Adam
Daniel-Henri Caignard
Beatrice Guardiola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Application granted granted Critical
Publication of ES2130548T3 publication Critical patent/ES2130548T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA INVENCION SE REFIERE A LOS COMPUESTOS DE FORMULA (I) EN LA QUE R1, R2, R2'', R2", R2"'', R3 Y N SON TALES COMO SE DEFINEN EN LA DESCRIPCION, SUS ISOMEROS OPTICOS, Y SUS SALES DE ADICION A UN ACIDO O UNA BASE FARMACEUTICAMENTE ACEPTABLE. MEDICAMENTOS.
ES95400496T 1994-03-11 1995-03-08 Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. Expired - Lifetime ES2130548T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9402813A FR2717175B1 (fr) 1994-03-11 1994-03-11 Nouveaux composés alkylaminoindanes, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.

Publications (1)

Publication Number Publication Date
ES2130548T3 true ES2130548T3 (es) 1999-07-01

Family

ID=9460912

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95400496T Expired - Lifetime ES2130548T3 (es) 1994-03-11 1995-03-08 Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Country Status (16)

Country Link
US (1) US5569669A (es)
EP (1) EP0671397B1 (es)
JP (1) JP2868429B2 (es)
CN (1) CN1055468C (es)
AT (1) ATE176467T1 (es)
AU (1) AU679607B2 (es)
CA (1) CA2144288A1 (es)
DE (1) DE69507652T2 (es)
DK (1) DK0671397T3 (es)
ES (1) ES2130548T3 (es)
FI (1) FI951091A (es)
FR (1) FR2717175B1 (es)
GR (1) GR3029657T3 (es)
NO (1) NO950921L (es)
NZ (1) NZ270686A (es)
ZA (1) ZA952019B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
ATE377585T1 (de) 1996-12-18 2007-11-15 Teva Pharma Aminoindanderivate
ATE275133T1 (de) * 1997-12-03 2004-09-15 Taisho Pharmaceutical Co Ltd 1,2-dihydro-2-oxochinolin-derivate
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
JP2009518433A (ja) * 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 神経保護用の低用量ラドスチギルの使用
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
CA3218884A1 (en) * 2021-05-11 2022-11-17 David Nutt Therapeutic aminoindane compounds and compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8707123D0 (en) * 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
US5140039A (en) * 1988-01-15 1992-08-18 Abbott Laboratories Aminomethyl-thiochroman compounds
DK0471515T3 (da) * 1990-08-15 1997-07-21 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner
HRP930210A2 (en) * 1992-02-25 1995-06-30 Recordati Chem Pharm Heterobicyclic compounds and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
CA2144288A1 (fr) 1995-09-12
FR2717175B1 (fr) 1996-06-14
NO950921D0 (no) 1995-03-10
GR3029657T3 (en) 1999-06-30
FI951091A0 (fi) 1995-03-08
DE69507652T2 (de) 1999-09-09
DK0671397T3 (da) 1999-09-20
EP0671397B1 (fr) 1999-02-03
NZ270686A (en) 1996-05-28
US5569669A (en) 1996-10-29
AU1472895A (en) 1995-09-21
NO950921L (no) 1995-09-12
EP0671397A1 (fr) 1995-09-13
JP2868429B2 (ja) 1999-03-10
DE69507652D1 (de) 1999-03-18
FR2717175A1 (fr) 1995-09-15
AU679607B2 (en) 1997-07-03
ATE176467T1 (de) 1999-02-15
ZA952019B (en) 1995-12-11
CN1111620A (zh) 1995-11-15
JPH07278068A (ja) 1995-10-24
FI951091A (fi) 1995-09-12
CN1055468C (zh) 2000-08-16

Similar Documents

Publication Publication Date Title
ES2130548T3 (es) Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR029604A2 (es) Intermediarios para la preparacion de citalopram y composicion farmaceutica antidepresiva que comprende el citalopram preparado
HRP20110384T1 (hr) Uporaba derivata benzo-kondenziranih heterocikličkih sulfamida za liječenje manije i bipolarnog poremećaja
ES2062458T3 (es) Derivados del 1,2-benzisoxazol, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
HRP20110726T2 (hr) Uporaba derivata benzo-kondenziranih heterocikliäśkih sulfamida za lijeäśenje pretilosti
ES534268A0 (es) Un procedimiento para la preparacion de derivados benzoicos.
PE20020692A1 (es) Compuestos derivados de benzotiofeno y su procedimiento de obtencion
CO4900053A1 (es) Derivados de sulfonamida y -n-(4-aril-tiazol-2-il) y su uso
BR9708480A (pt) Uso dos derivados das tetrahidro-beta-cabolinas como agentes antimetastáticos
ATE34972T1 (de) Leukotrienantagonisten.
NO871861L (no) Fremgangsmaate for fremstilling av nye dopamin beta-hydroxylase inhibitorer.
ES2143154T3 (es) Compuestos alcoxi-arilos con afinidad para los receptores melatoninergicos, sus procedimientos de preparacion, y las composiciones farmaceuticas que los contienen.
ES2153019T3 (es) Derivados de benzo-dioxano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
DK0431579T3 (da) Substituerede cyclohexener som midler med virkning på centralnervesystemet
DE69603667D1 (de) Indol-, Indazol- und Benzisoxazolderivate zur Behandlung von Schizophrenia
SG164268A1 (en) Quinolin-4-yl derivatives i
KR870007149A (ko) 하이드록시아세트산 유도체의 제조방법
AR009274A1 (es) Un composicion farmaeutica que incluye tropnilpiperazinas como ligandos del receptor d4 de dopamina, compuestos, usos para la preparacion demedicamentos y procedimiento de preparacion de los compuestos.
AR052261A1 (es) Derivados de fenilpiperazina con una combinacion de agonismo parcial del receptor de dopamina -d2 e inhibicion de la reabsorcion de serotonina, composiciones farmacéuticas que los contienen y su empleo como medicamentos para el tratamiento de enfermedades del sistema nervioso central.
AR050178A1 (es) Procedimiento de fotorracemizacion
ES535628A0 (es) Procedimiento para preparar nuevos compuestos heterociclicos
PE20020475A1 (es) Derivados de acido propionico como moduladores del receptor proliferador de peroxisoma ppar-o
AR029539A1 (es) Combinaciones de estatinas y agentes estrogenicos
PT83630B (pt) Processo para a obtencao de derivados da 3-imino-piridazina
AR008450A1 (es) Derivados de 1-carba-(detia)-cefalosporina, procedimientos para su obtencion, preparaciones farmaceuticas que los comprenden, empleo de los mismosy compuestos utiles como intermediarios en la obtencion de los mismos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 671397

Country of ref document: ES